Tandem inks distribution deal in Scandinavia for insulin pumps

Tandem Diabetes Care (NSDQ:TNDM) has inked a distribution agreement with Rubin Medical to commercialize the medical device company’s t:slim X2 insulin pump, insulin cartridges and t:lock infusion sets in Sweden, Norway and Denmark.

According to the terms of the deal, Rubin Medical is slated to perform all sales, marketing and customer training for Tandem’s devices.

“This represents the first pump distribution agreement for Tandem Diabetes Care outside of the United States and is a significant step forward for our international commercialization strategy,” Tandem’s president & CEO, Kim Blickenstaff, said in prepared remarks.

“Rubin Medical’s proven success with insulin pumps in Sweden, Norway and Denmark, and their demonstrated support of patients and clinicians impacted by diabetes, make them an ideal distributor for us in these countries,” he added.

“We are thrilled to be able to bring the first touchscreen insulin pump to our diabetes communities in Scandinavia,” Karl-Johan Öhman, CEO & managing director of Rubin Medical, said. “We believe the t:slim X2 Pump will be well received in these countries. We’re very happy to add this product to our portfolio and to be one of the first markets outside of the United States to offer this exciting option to patients and clinics.”

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Theranos whistleblower Tyler Shultz to participate in keynote interview at DeviceTalks Boston At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos. Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston. REGISTER NOW